Issues of Practical Colposcopy Genital Infections · Mar 30, 2026
Focus on new treatment options for genitourinary syndrome of menopause and vulvovaginal atrophy
By Олеговна ДС, Михельсон А, Karachevskaya O
In postmenopausal women, the physiological decline in levels of estrogens, androgens, and their precursor, dehydroepiandrosterone (ДГЭА), leads to atrophic changes in the tissues of the genitourinary tract. These changes manifest not only as dryness and irritation of the vaginal mucosa and pain during sexual intercourse or a routine gynecological examination, but also as a range of urinary symptoms: frequent urination, nocturia, urgency, recurrent cystitis, and urinary incontinence. These symptoms often receive insufficient attention from physicians and patients themselves, as they are perceived as natural age-related changes during postmenopause. The article presents current data on the pathogenesis of postmenopausal changes, including changes in the urogenital epithelium, disruption of the vaginal microbiome, and reduced local synthesis of sex hormones in genitourinary tissues. Particular attention is paid to the intravaginal use of ДГЭА (prasterone), a drug that acts according to the principle of intracrinology: as a prodrug, prasterone provides tissue-specific formation of androgens and estrogens directly within the cells of the vulvovaginal region and lower urinary tract, without exerting systemic effects. Results of clinical studies are presented that confirm the efficacy of prasterone in reducing both genital and urinary symptoms, including manifestations of overactive bladder, as well as the safety of the drug during long-term use. A clinical case is presented illustrating the efficacy of prasterone in treating a patient with genitourinary syndrome of menopause and sexual dysfunction. In postmenopausal women, the physiological decline in estrogen, androgen, and their precursor – dehydroepiandrosterone (DHEA) – leads to atrophic changes in the genitourinary tract. These changes manifest not only as vaginal dryness, irritation, and dyspareunia (including pain during routine gynecological examination), but also as a broad spectrum of urinary symptoms: urinary frequency, nocturia, urgency, recurrent cystitis, and even urinary incontinence. Despite their significant impact on quality of life, these symptoms are often overlooked by both clinicians and patients, who tend to regard them as inevitable consequences of aging. This article reviews current evidence on the pathophysiology of postmenopausal genitourinary changes, including atrophy of the urogenital epithelium, disruption of the vaginal microbiome, and diminished local sex hormone synthesis within genital and lower urinary tract tissues. Special emphasis is placed on intravaginal DHEA (prasterone) – a prohormone that acts via the principle of intracrinology. Once administered, prasterone is converted locally into active androgens and estrogens directly within the cells of the vulvovaginal and lower urinary tract tissues, without exerting systemic hormonal effects. Clinical trial data are presented demonstrating that prasterone significantly alleviates both genital and urinary symptoms, including those associated with overactive bladder, while maintaining a favorable safety profile during long-term use. A representative clinical case is also included to illustrate real-world therapeutic outcomes.